Dyax Corp. Announces First Market Approval from Licensing and Funded Research Program
Thursday February 28, 2:00 pm ET
- Peptide ligand used in purification process during manufacture of Wyeth's XYNTHA(TM) -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX - News) announced today that Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE - News), recently received market approval from the U.S. Food and Drug Administration for XYNTHATM (Antihemophilic Factor [Recombinant], Plasma/Albumin-Free), a recombinant factor VIII product, for patients with hemophilia A for both the control and prevention of bleeding episodes and surgical prophylaxis. The peptide ligand, used in the purification process during the manufacture of XYNTHA, was discovered utilizing Dyax’s proprietary phage display library and is part of the Company’s Licensing and Funded Research Program (LFRP). XYNTHA is now distinguished as the only recombinant factor VIII treatment to utilize an entirely synthetic purification process.
Under the terms of the license agreement with Wyeth, Dyax is entitled to a milestone payment triggered by the first commercial sale of XYNTHA followed by royalties based on certain pre-determined sales levels.
“This announcement marks a significant milestone for our maturing Licensing and Funded Research Program and further validates the strengths of our proprietary phage display technology. Currently there are several clinical candidates in late Phase 2 trials in this program,” commented Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax. “The LFRP has the potential to generate substantial revenue as licensees and collaborators, like Wyeth, advance product candidates to commercialization.”... |
